Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder.  

Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Agomelatine has been shown as an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and major depressive disorder (MDD) in Australia and the European Union (EU). In GAD, compared to standard of care drugs, agomelatine has demonstrated benefits such as reduced risk of abuse potential, sexual dysfunction, and weight gain. However, over 90% of unmodified agomelatine is lost to first-pass liver metabolism and its use has been limited by dose-dependent liver enzyme elevations and the need for frequent liver monitoring. 

Seaport has used its Glyph platform to enable GlyphAgo to overcome this limitation by shifting absorption towards the intestinal lymphatics, avoiding first-pass liver metabolism, and increasing systemic exposure of agomelatine. The company hopes that GlyphAgo has the potential to achieve exposure levels that have demonstrated efficacy in GAD at a lower dose that does not cause an increase in liver enzymes and reduces or eliminates the need for liver function testing. 

The study will evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo in healthy adult volunteers. The dosing now means that Seaport has two therapeutic candidates currently in clinical development.  

“Anxiety disorders are the most prevalent neuropsychiatric disorders, impacting nearly 30% of adults at some point in their lives, with GAD alone affecting approximately 100 million adults worldwide. Despite this, in the US no new drugs or mechanisms have been approved for GAD in decades,” said Antony Loebel, Chief Medical Officer, President of Clinical Development at Seaport Therapeutics. “Our Phase I proof-of-concept study could be highly derisking for the GlyphAgo programme, as agomelatine’s efficacy in GAD is already well established. The key question is whether we can achieve effective exposure at a lower dose, which would demonstrate GlyphAgo’s ability to avoid agomelatine’s dose-dependent liver issues. We believe GlyphAgo has the potential to redefine the treatment landscape for GAD and represents an important clinical advancement for patients.” 

Reece Armstrong, Editor, DDW